Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome
Tracking Information | |||||
---|---|---|---|---|---|
First Received Date ICMJE | October 6, 2011 | ||||
Last Updated Date | February 3, 2012 | ||||
Start Date ICMJE | March 2011 | ||||
Estimated Primary Completion Date | September 2012 (final data collection date for primary outcome measure) | ||||
Current Primary Outcome Measures ICMJE |
Levels of Glycosaminoglycan (GAG) and other biomarkers of lysosomal function levels in CSF [ Time Frame: GAG and biomarkers assessed on study Day 1 ] [ Designated as safety issue: No ] GAGs including sulfated DS/HS oligosaccharides and GAG degradation products |
||||
Original Primary Outcome Measures ICMJE | Same as current | ||||
Change History | Complete list of historical versions of study NCT01449240 on ClinicalTrials.gov Archive Site | ||||
Current Secondary Outcome Measures ICMJE |
Levels of Glycosaminoglycan (GAG) and other biomarkers of lysosomal function levels in urine [ Time Frame: GAG and other biomarkers assessed on study Day 1 ] [ Designated as safety issue: No ] GAGs including sulfated DS/HS oligosaccarides and GAG degradation products |
||||
Original Secondary Outcome Measures ICMJE | Same as current | ||||
Current Other Outcome Measures ICMJE | |||||
Original Other Outcome Measures ICMJE | |||||
Descriptive Information | |||||
Brief Title ICMJE | Collection and Study of Cerebrospinal Fluid in Patients With Hunter Syndrome | ||||
Official Title ICMJE | A Cerebrospinal Fluid Collection Study in Pediatric and Adult Patients With Hunter Syndrome | ||||
Brief Summary | The purpose of the study is to collect data on CSF biomarkers in patients with Hunter Syndrome that would serve as reference data for comparison with cognitively impaired patients with Hunter syndrome, patients with other lysosomal storage diseases, or other diseases with CNS involvement. |
||||
Detailed Description | To determine levels of glycosaminoglycans (GAGs), including dermatan sulfate (DS) and heparan sulfate (HS), GAG-degradation products, and other biomarkers of central nervous system (CNS) and lysosomal function in cerebrospinal fluid (CSF) in pediatric and adult patients with Hunter syndrome. |
||||
Study Type ICMJE | Observational | ||||
Study Design ICMJE | Observational Model: Case-Only Time Perspective: Prospective |
||||
Biospecimen | Retention: Samples Without DNA Description: CSF and urine samples will be retained and analyzed for glycosaminoglycans (GAGs), including sulfated DS/HS oligosaccharides, GAG-degradation products, and other biomarkers of CNS or lysosomal function. |
||||
Sampling Method | Non-Probability Sample | ||||
Study Population | The study population will consist of pediatric (<18 years of age) and adult (≥18 years of age) male patients with Hunter syndrome. Up to approximately 60 patients (approximately 30 adults and 30 children) may be enrolled in this study. |
||||
Condition ICMJE | Hunter Syndrome | ||||
Intervention ICMJE | Other: No treatment will be administered in this study
No treatment will be administered in this study |
||||
Study Group/Cohort (s) | Adults and Children with Hunters
Approx 30 adult (equal to or not less than 18yrs old) and 30 children (equal to or not over 18yrs old)
Intervention: Other: No treatment will be administered in this study |
||||
Publications * |
|
||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||
Recruitment Information | |||||
Recruitment Status ICMJE | Recruiting | ||||
Estimated Enrollment ICMJE | 60 | ||||
Estimated Completion Date | September 2012 | ||||
Estimated Primary Completion Date | September 2012 (final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||
Gender | Male | ||||
Ages | up to 70 Years | ||||
Accepts Healthy Volunteers | No | ||||
Contacts ICMJE |
|
||||
Location Countries ICMJE | United States, United Kingdom | ||||
Administrative Information | |||||
NCT Number ICMJE | NCT01449240 | ||||
Other Study ID Numbers ICMJE | HGT-HIT-072 | ||||
Has Data Monitoring Committee | No | ||||
Responsible Party | Shire Human Genetic Therapies, Inc. | ||||
Study Sponsor ICMJE | Shire Human Genetic Therapies, Inc. | ||||
Collaborators ICMJE | |||||
Investigators ICMJE |
|
||||
Information Provided By | Shire Human Genetic Therapies, Inc. | ||||
Verification Date | February 2012 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |